The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.
Western blotting: Recommended dilution: 0.5 μg/mL.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1 mg/mL
Buffer
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Do not freeze.
Lagerung
4 °C
Informationen zur Lagerung
Store at 2-8°C. Do not freeze.
Hallengärd, Haller, Petersson, Boberg, Maltais, Isaguliants, Wahren, Bråve: "Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity." in: Vaccine, Vol. 29, Issue 4, pp. 839-48, (2011) (PubMed).
Bartonová, Král, Sieglová, Brynda, Fábry, Horejsí, Kozísek, Sasková, Konvalinka, Sedlácek, Rezácová: "Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies." in: Antiviral research, Vol. 78, Issue 3, pp. 275-7, (2008) (PubMed).
OLoughlin, Greene, Matsumura: "Diversification and specialization of HIV protease function during in vitro evolution." in: Molecular biology and evolution, Vol. 23, Issue 4, pp. 764-72, (2006) (PubMed).
Lescar, Brynda, Rezacova, Stouracova, Riottot, Chitarra, Fabry, Horejsi, Sedlacek, Bentley: "Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody." in: Protein science : a publication of the Protein Society, Vol. 8, Issue 12, pp. 2686-96, (2000) (PubMed).
Target
HIV Protease
Substanzklasse
Viral Protein
Hintergrund
The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein products that are essential for its assembly and subsequent activity. This maturation process occurs as the virion buds from the host cell. HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lower the viral load carried by AIDS patents.,HIV-1 PR, HIV-2 PR